Desperate to shed those unwanted pounds? Hate dragging yourself to the gym?
Soon, you might be able to lose weight without the work!
How? In the never-ending battle of bulge, new medications are in trials that could soon tip the scales in your favor.
Oh, we know new drugs don't also fly with the FDA - but in this case the odds are in your favor.
The feds aren't considering 1 new drug; not even 2 new drugs -- you guessed it, 3 unique and promising weight-loss drugs are under review.
And they're being developed by three different companies with Vivus and Arena Pharmaceuticals expecting a decision in late October and Orexigen facing the agency's decision in early 2011.
But can these pharma stocks gain as quickly as their drugs make overweight patients lose? The numbers speak for themselves.
Thomson Reuters estimates that by 2013 lorcaserin from Arena will generate sales of $418 million, Qnexa from Vivus will generate sales of $357 million and Contrave from Orexigen will generate sales of $325 million.
And that may be the tip of the iceberg. The global obesity drug treatment market is expected to generate $1.5 billion in sales by 2014, according to research from Decision Resources.
Learn more about this trend. Watch the video above!
Read More:
> Fast Personal Pt. 1: Meds For The Masses
> Fast Personal Pt. 2: Plastic Profits - The Business Of Beauty
> Fast Personal Pt. 3: Rise Of Robotic Surgeons
*Luke Bauer contributed to this report
______________________________________________________
Got something to to say? Send us an e-mail at fastmoney-web@cnbc.com and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send those e-mails to fastmoney@cnbc.com.
Trader disclosure: On June 24, 2010, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Adami owns (AGU), (BTU), (NUE), (C), (GS), (INTC), (MSFT); Adami’s wife works at Merck; Finerman and Finerman’s Firm owns (AAPL); Finerman’s Firm owns (AEO); Finermans’ Firm owns (ANF); Finerman’s Firm owns (BAC) stock and calls; Finerman and Finerman’s Firm own (BAC) preferred; Finerman and Finerman’s Firm owns (BBY); Finerman owns (BP) calls; Finerman and Finerman’s Firm owns (C); Finerman and Finerman’s Firm own (CVS); Finerman owns (GLW); Finerman & Finerman’s Firm owns (GOOG); Finerman & Finerman’s Firm owns (HPQ); Finerman & Finerman’s Firm owns (IBM); Finerman & Finerman’s Firm owns (JPM) stock & calls; Finerman’s firm owns (PM); Finerman’s Firm owns (RIG); Finerman’s Firm owns (TGT); Finerman’s Firm owns (WMT); Finerman’s Firm is short (IJR); Finerman’s Firm is short (IWM); Finerman’s Firm is short (MOY); Finerman’s Firm is short (SPY); Jon Najarian owns (TGT) and short calls; Jon Najarian owns (WMT) and short calls; Jon Najarian owns (AAPL) call spreads; Jon Najarian owns (ODP) call spreads; Grasso owns (ASTM), (ABK), (BAC), (BGP), (C), (DYN), (JPM), (LPX), (NDAQ), (PRST); Seymour Owns (AAPL), (BAC), (GOOG)
For Tim Seymour:
Seygem Asset Management Owns (WBD)
For Steve Grasso:
Stuart Frankel & Co and it’s partners own (BAX)
Stuart Frankel & Co and it’s partners own (CUBA)
Stuart Frankel & Co and it’s partners own (DHR)
Stuart Frankel & Co and it’s partners own (DYN)
Stuart Frankel & Co and it’s partners own (GERN)
Stuart Frankel & Co and it’s partners own (HSPO)
Stuart Frankel & Co and it’s partners own (MERC)
Stuart Frankel & Co and it’s partners own (NWS.A)
Stuart Frankel & Co and it’s partners own (NYX)
Stuart Frankel & Co and it’s partners own (PDE)
Stuart Frankel & Co and it’s partners own (PFE)
Stuart Frankel & Co and it’s partners own (PRST)
Stuart Frankel & Co and it’s partners own (RDC)|
Stuart Frankel & Co and it’s partners own (SYMC)
Stuart Frankel & Co and it’s partners own (TLM)
Stuart Frankel & Co and it’s partners own (TRV)
Stuart Frankel & Co and it’s partners own (XRX)
Stuart Frankel & Co and it’s partners own (SDS)
Stuart Frankel & Co and it’s partners own (TBT)
Stuart Frankel & Co and it’s partners are short (QQQQ)
Stuart Frankel & Co and it’s partners are short (AAPL)
Barry Ritholtz
Funds managed by Fusion IQ own (BJ)
Pavel Malvhanov|
***No Disclosures**
Colin Gillis
***No Disclosures**
Christopher Whalen
***No Disclosures**
James Paulson
Paulson owns (SPY)
CNBC.com with wires
